235 related articles for article (PubMed ID: 27226830)
21. Pharmaceutical pricing and reimbursement reforms in Greece.
Yfantopoulos J
Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia.
Tesar T; Golias P; Masarykova L; Kawalec P; Inotai A
Front Pharmacol; 2021; 12():795002. PubMed ID: 34966285
[No Abstract] [Full Text] [Related]
23. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
Lee HJ; Han E; Kim H
Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
[TBL] [Abstract][Full Text] [Related]
24. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
Barszczewska O; Piechota A
Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
[TBL] [Abstract][Full Text] [Related]
26. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
[TBL] [Abstract][Full Text] [Related]
27. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.
Vogler S; Habl C; Bogut M; Voncina L
Croat Med J; 2011 Apr; 52(2):183-97. PubMed ID: 21495202
[TBL] [Abstract][Full Text] [Related]
28. The drug budget silo mentality: the French case.
Le Pen C
Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
[TBL] [Abstract][Full Text] [Related]
29. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
Grewal S; Ramsey S; Balu S; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
[TBL] [Abstract][Full Text] [Related]
30. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.
de Jager H; Suleman F
Int J Clin Pharm; 2019 Feb; 41(1):81-87. PubMed ID: 30478491
[TBL] [Abstract][Full Text] [Related]
31. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
[TBL] [Abstract][Full Text] [Related]
32. Pharmaceutical policies in European countries.
Barros PP
Adv Health Econ Health Serv Res; 2010; 22():3-27. PubMed ID: 20575226
[TBL] [Abstract][Full Text] [Related]
33. Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
Godman B; Shrank W; Wettermark B; Andersen M; Bishop I; Burkhardt T; Garuolienè K; Kalaba M; Laius O; Joppi R; Sermet C; Schwabe U; Teixeira I; Tulunay FC; Wendykowska K; Zara C; Gustafsson LL
Pharmaceuticals (Basel); 2010 Aug; 3(8):2470-2494. PubMed ID: 27713363
[TBL] [Abstract][Full Text] [Related]
34. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
35. Estimating Potential for Drug Budget Reallocation Following Expiration of Exclusivity of Pharmaceutical Products.
Toghanian S; Moshtaghi-Svensson J; Papageorgiou M; Kittelsen K; Dolk C; Hultstrand M; Salomonsson S
J Health Econ Outcomes Res; 2022; 9(1):20-30. PubMed ID: 35178466
[No Abstract] [Full Text] [Related]
36. Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries.
Atikeler EK; Özçelikay G
Springerplus; 2016; 5(1):1876. PubMed ID: 27833835
[TBL] [Abstract][Full Text] [Related]
37. The economics of biosimilars.
Blackstone EA; Joseph PF
Am Health Drug Benefits; 2013 Sep; 6(8):469-78. PubMed ID: 24991376
[TBL] [Abstract][Full Text] [Related]
38. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
Aladul MI; Fitzpatrick RW; Chapman SR
Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
[TBL] [Abstract][Full Text] [Related]
39. An analysis of orphan medicine expenditure in Europe: is it sustainable?
Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]